Sign inJoin waitlistJoin the waitlist

Charles Erlichman

Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · ·

History

Mayo Clinic College of Medicine and Science
Present

Fellow American College of Physicians
National Institutes of Health
Medical Oncology
Medicine Toronto Western Hospital
Medicine Mount Sinai Hospital
UNIV OF TORONTO, TORONTO

Research

A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
Journal of Clinical Oncology · 1988 · First of 4 authors · 550 citations
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
Journal of Clinical Oncology · 2005 · Last of 10 authors · 388 citations
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Journal of Clinical Oncology · 2018 · 376 citations

Alex Adjei
39 papers
HP
Henry Pitot
31 papers
Scott Kaufmann
29 papers
JR
Joseph Rubin
21 papers
RG
Richard Goldberg
20 papers
SA
Steven Alberts
18 papers
Julian Molina
13 papers
Keith Bible
13 papers
GK
George Kim
12 papers
Matthew Goetz
12 papers · 2 as a fellow
PH
Paul Haluska
12 papers
WM
William Maples
12 papers

Grants

NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
National Cancer Institute · UM1
PI · $560K · Mayo Clinic Rochester
2014–2019
Early Therapeutics Development with Phase Ii Emphasis
National Cancer Institute · N01
Contact PI · $3.5M · Mayo Clinic Rochester
2011–2014
Phase I Clinical Trials of Anticancer Agents
National Cancer Institute · U01
Contact PI · $9.8M · Mayo Clinic Rochester
1995–2014
Early Therapeutics Development with Phase II Emphasis
National Cancer Institute · N01
Contact PI · $5.1M · Mayo Clinic Rochester
2006–2011

Clinical trials

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 1
Mayo Clinic
2012–2018
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2009–2027
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 1
Mayo Clinic
2008–2014
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
Principal investigator · Terminated
Mayo Clinic
2007–2010